Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (636)
  2. Journal Article (498)
  3. Review (141)
  4. Editorial (64)
  5. Research Letter (50)
  6. Correspondence (14)
  7. Guidelines (6)
  8. Book Section (3)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Department of Medicine (1155)
  2. Graduate Medical Education (1109)
  3. GME, Medicine (1085)
  4. Hematologic Malignancies, Division of (744)
  5. Weinberg Fellows (652)
  6. Solid Tumor Oncology Division (612)

More Groups

People
  1. Jan Bewersdorf (102)
  2. Zachary Epstein-Peterson (93)
  3. Gunjan Shah (91)
  4. Maria Palomba (91)
  5. Gilles Salles (86)
  6. Michael Scordo (85)

More People

Years
  1. 2025 (152)
  2. 2024 (357)
  3. 2023 (296)
  4. 2022 (222)
  5. 2021 (159)
  6. 2020 (114)

More Years

Publications
  1. Blood (287)
  2. Journal of Clinical Oncology (217)
  3. Clinical Cancer Research (38)
  4. Annals of Oncology (35)
  5. Cancer Research (35)
  6. Journal of Thoracic Oncology (30)

More Publications

Publishers
  1. American Society of Hematology (322)
  2. American Society of Clinical Oncology (248)
  3. Elsevier Inc. (141)
  4. Nature Publishing Group (106)
  5. American Association for Cancer Research (104)
  6. Oxford University Press (61)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of therapies following discontinuation of non-covalent Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and Richter transformation: Results from an international, multicenter study
    Meeting Abstract

    Thompson, M. C.; Bhat, S. A.; Jurczak, W.; Patel, K.; Shah, N. N.; Woyach, J. A.; Coombs, C. C.; Eyre, T. A.; Danecki, M.; Dlugosz-Danecka, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic characterization and classification of BCL6 rearranged follicular lymphomas
    Meeting Abstract

    Amallraja, A.; Gundem, G.; Domenico, D.; Ossa, J. E. A.; Aypar, U.; Baik, J.; Kluk, M.; Sethi, S.; Lopez, K.; Qualls, D. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Adult AML patients with NUP98 fusions are frequently therapy-related, and are associated with monocytic differentiation, recurring mutations in NRAS, DNMT3A and WTI and poor outcome
    Meeting Abstract

    Yao, J.; Aypar, U.; Sethi, S.; Boussi, L.; Londono, D.; Sukhadia, P.; Berman, E.; Stein, E. M.; Dogan, A.; Xiao, W.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia
    Meeting Abstract

    Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Artificial-intelligence, data-driven, comprehensive classification of myeloid neoplasms based on genomic, morphological and histological features
    Meeting Abstract

    Lanino, L.; D'Amico, S.; Maggioni, G.; Ali, N. H. A.; Wang, Y. H.; Gurnari, C.; Gagelmann, N.; Bewersdorf, J. P.; Ball, S.; Guglielmelli, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Survival and therapeutic outcomes in T-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort
    Meeting Abstract

    Braunstein, Z.; McLaughlin, E.; Lingamaneni, P.; Barta, S. K.; Cao, M.; Chang, T.; Ganesan, N.; Luu, B.; Mehta-Shah, N.; Shree, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study
    Meeting Abstract

    Thompson, M. C.; Parrondo, R. D.; Frustaci, A. M.; Allan, J. N.; Ghia, P.; Mocanu, I.; Tam, C. S.; Trotman, J.; Ahn, I. E.; Stilgenbauer, S.; more...
    Blood (2024)

    Fulltext@MSK | Save